ChromoGenics: Entering 2024 with the ambitious Skanska collaboration in focus - Redeye

Redeye provides an update on ChromoGenics following the company's Q4 2023 results. A weak quarter closed a tough 2023. But with recent successful capital increase, and a few good projects in the pipeline, 2024 looks promising.

Länk till analysen i sin helhet: https://www.redeye.se/research/969968/chromogenics-entering-2024-with-the-ambitious-skanska-collaboration-in-focus?utm_source=finwire&utm_medium=RSS